Proactive: You've completed patient enrollment for the pancreatic cancer cohorts in your phase 1b/2a clinical trial. That's another milestone for the trial. This trial, conducted in conjunction with a university cancer center, allows us to see pre- and post-treatment biopsies of the tumors. This provides us with physiological and quantitative information regarding cytotoxic T cell infiltration of the tumors. It corroborates in humans what we've previously seen in animals and anecdotally in other studies – t ...

Contact: Lisata Therapeutics, Inc. John Menditto Vice President, Investor Relations and Corporate Communications Phone: 908-842-0084 Email: jmenditto@lisata.com Media: ICR Westwicke Elizabeth Coleman Senior Associate Phone: 203-682-4783 Email: elizabeth.coleman@westwicke.com Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, ...

BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial. This investigatorinitiated trial, led by Dr. Anup Kasi at The University of Kansas ("KU") Cancer Center, is eval ...

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed 'a 180' turn since the peak of Covid vaccines interest in the sector in 2021. Risk capital has been sidelined during this politically and economically volatile period, not just in life sciences, but across microcap markets internationally. Still, for those would-be in ...

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June: BIO International Convention (June 3-6, 2024) Format: In-person Location: San Diego, California Presentation Date: Monday, June 3, 2024 Presentation Time: 2:15 p.m ...

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June: BIO International Convention (June 3-6, 2024) Format: In-person Location: San Diego, California Presentation Date: Monday, June 3, 2024 Presentation Time: 2:15 p.m ...

About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical writing. Other jobs ha ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "E ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "E ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer James Nisco – Chief Accounting Officer Conference Call Participants Sara Nik – H.C. Wainwright Will Hidell – Brookline Capital Markets Pete Enderlin – MAZ Partners Steve Bro ...